Scientific Advisors

Dr. Peter K. Vogt
Professor, Dept. of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA

Dr. Vogt research is on mechanisms of cancer. He served as a scientific advisor to both Microgenics and Calydon. He is a member of the National Academy of Sciences.

 

Sir John Skehel FRS FMedSci
Secretary, Biological Sciences Division, Royal Society of London

Sir John Skehel FRS FMedSci was Director of the National Institute for Medical Research (UK) from 1987 to 2006, Director of the WHO World Influenza Centre from 1975 to 1993, and currently is Secretary, Biological Sciences Division, Royal Society of London.  His research is on the structure and functions of the influenza virus hemagglutinin (HA) and neuraminidase (NA) membrane glycoproteins. He is a member of the National Academy of Sciences. 

 

Dr. Peter A. Barry
Director, Center for Comparative Medicine, University of California, Davis

Dr. Barry was Director of the California National Primate Research Center at Davis. His research is on mechanisms of cytomegalovirus (CMV) persistence and pathogenesis, as well as human CMV vaccine strategies as tested in non-human primate models.

 

Dr. Steve F. Dowdy
Professor, Cellular and Molecular Medicine, University of California, San Diego, School of Medicine

Dr. Dowdy research interests include mechanisms of G1 cell cycle progression, macromolecular drug delivery using TAT Peptide Transduction Domains, mRNA replicons, RNAi and a class of RNAi pro drugs known as RiboNucleic Neutrals (RNN).

 

Dr. John H. Crowe
Professor of Molecular and Cellular Biology, Emeritus and Director of the Center for Biostabilization Emeritus at UC Davis.

Dr. Crowe is well known for work on stabilization of biomaterials in the frozen and dry states, with many applications in pharmacy and clinical medicine, and he holds, with the University of California, numerous patents in this field.  He is a Fellow of the American Association for the Advancement for Science, Fellow of the Society for Cryobiology, Fulbright Senior Research Scholar, Guggenheim Fellow, and serves on numerous editorial boards for scientific journals. His work was recently featured on NPR’s Science Friday

 

Vaccine Vision

A broad family of room temperature stable vaccines self administered via a painless patch...

read more
Featured Article
Featured Team Member

Dr. D. R. Henderson
Chief Executive Officer

Dan has experience and success in founding and building biopharmaceutical companies. He holds a Ph.D. in Medical Sciences from the University of New Mexico School of Medicine and was a postdoctoral scholar at Duke University Medical Center. He founded Microgenics Corporation. At Microgenics, Dan invented the CEDIA™ immunoassay system used in clinical laboratories throughout the world. CEDIA™ immunoassays now sell over $1B annually: please see www.usdiagnostics.roche.com and then search for CEDIA™ on their website; repeat at www.thermofisher.com. For this work, the American Association for Clinical Chemistry (AACC) awarded the 2015 biennial Ullman Prize for Technology Innovation to Dr. Henderson.

Dan also founded Calydon where he genetically engineered adenovirus targeting prostate cancer. For this work he was recognized as one of the two pioneers in the field of oncolytic virotherapy (Scientific American, “Tumor Busting Viruses”, October 2003). Calydon was sold to Cell Genesys. 2015 saw the first FDA approved oncolytic virus, a herpesvirus for melanoma.

Dr. Henderson also co-founded PaxVax, a manufacturer and developer of vaccines for travelers to countries without adequate water sanitation (Typhoid, Cholera and Hepatitis A) and the U.S. Military (Anthrax) (see www.paxvax.com). PaxVax was named Best Early-Stage Vaccine Biotech company at the 16th annual World Vaccine Congress in Washington, D.C., March, 2016 and received FDA approval for a Single Dose Oral Cholera vaccine in June. Dan holds 34 issued US Patents.

read more